|
Author, year reference | Sex/age | Tumor type | Ki67 (%) | MGMT | TMZ (mg/m2) & schedule (no. cycles) | MRI (% shrinkage) | Clinical outcome |
|
Thearle et al., 2011 [16] | M/50 | ACTH SA Ad → Ca → NS | 31 | NA | 200 × 5/28 + CAP (4) | Reduced (75) | Death |
|
Dillard et al., 2011 [17] | M/56 | ACTH Ad | 5-6 | NA | 150–200 × 5/28 (4) | Reduced (60) | CR |
|
Annamalai et al., 2012 [18] | M/65 | ACTH Ca | 5–15 | Low | 200 × 5/28 (15) | PR of METS | “Remained well” |
|
Moshkin et al., 2011 [19] | M/46 | ACTH SA Ad → Ca | 1–5 | (+) | 200 × 5/28 (16) | No change | Progression |
|
Zacharia et al., 2014 [20] | M/50 | ACTH Ad | <5 | (−) |
150, 5/28 + CAP (30) | SD | PR |
F/46 | ACTH Ad | 15–20 | (−) | 150, 5/28 + CAP (32) | CR | CR |
M/44 | ACTH Ad | <5 | (−) | 150, 5/28 (45) + CAP + A-SST | CR | CR |
|
Raverot et al., 2010 [21] | M/31 | ACTH Ca → NS | 20 | 50 (+) | 150–200 × 5/28 | No change | NA |
M/49 | ACTH Ad | 20 | <1 | 150–200 × 5/28 | No change | NA |
M/38 | ACTH Ca | 10 | 30 (+) | 150–200 × 5/28 | SR | “Significant response” |
F/42 | ACTH Ad | 0.5 | 0 | 150–200 × 5/28 | SR | “Significant response” |
M/32 | PRL Ca | NA | NA | 150–200 × 5/28 (24) | Reduced (60), disappearance of METS | NA |
M/52 | PRL Ad | 0.5 | 30 | 150–200 × 5/28 (8) | No change | NA |
M/54 | PRL Ca | 1 | 0 | 150–200 × 5/28 (5) | No change | NA |
F/30 | PRL Ca | 10 | 100 | 150–200 × 5/28 (3) | No change | NA |
|
Bush et al., 2010 [22] | NA | Null cell Ad | <3 | — | 75 × 21/7 (10) | Reduced (20) | Stable |
NA | ACTH Ad | 18 | <10 | 75 × 21/28 (11) | Reduced (80) | “Improved” |
NA | NF Ad | <3 | 10–50 |
75 × 21/(13) | SD | SD |
NA | Null cell Ad | 6 | >50 | 75 × 21/7 (10) | SD | SD |
NA | PRL Ad | NA | <10 | 75 × 21/7 (11) | Reduced (80) | “Improved” |
NA | Null cell Ca | >20 | >50 | 75 × 21/7 (2) | SD × 2 months | NA |
NA | Null cell Ca | >20 | <10 | 75 × 21/7 (7) | Progression | Death |
|
Hirohata et al., 2013 [23] | M/59 | NF Ca | 74.6 | (+) | 150–200 × 5/28 (5) | PR | NA |
F/42 | ACTH Ca | 3.4 | (−) | 150–200 × 5/28 (7) | PR | NA |
F/60 | PRL Ca | 18.7 | (−) | 150–200 × 5/28 (13) | CR | NA |
M/23 | NF Ca | 2.5 | (+) | 150–200 × 5/28 (7) | SD | NA |
F/53 | ACTH Ca (Crooke cell) | 2.0 | (+) | 150–200 × 5/28 (20) | CR | NA |
F/60 | PRL Ca | 27.8 | (+) | 150–200 × 5/28 (12) | PR | NA |
M/57 | ACTH Ca | 10 | (+) | 150–200 × 5/28 (8) | SD | NA |
F/73 | NF Ca | 5.6 | (−) | 150–200 × 5/28 (22) | PR | NA |
M/60 | PRL Ca | 40.2 | (−) | 150–200 × 5/28 (24) | PR | NA |
F/61 | NF Ca | 12.2 | (+) | 75 × 6 weeks + RT | Progression | NA |
F/66 | PRL Ad | 9.4 | (−) | 75 × 6 weeks + RT | CR | NA |
F/49 | PRL Ad | 3.9 | (−) | NA (3) | Progression | NA |
F/45 | ACTH Ad (Crooke cell) | 46.8 | (+) | 150–200 × 5/28 (11) | PR | NA |
|
Losa et al., 2010 [24] | M/64 | ACTH Ad | NA | NA | 150–200 × 5/28 | Progression | Death |
M/52 | ACTH Cd | 1 | (−) | 150–200 × 5/28 | “Response” | Required GC therapy |
F/55 | ACTH Ad → NS | 5 | (−) | 150–200 × 5/28 | SD | NA |
F/53 | ACTH Ad | 2.5 | (+) | 150–200 × 5/28 | Progression | No change |
M/62 | PRL Ad | 9 | (−) | 150–200 × 5/28 | SD | NA |
F/57 | PRL Ad | NA | Noninformative | 150–200 × 5/28 | “Response” | “Improved” |
|
Moyes et al., 2009 [25] | F/64 | ACTH Ad → NS | “High” | (−) | 200 × 5/28 (6) | “Marked shrinkage” | “Improved” |
|
Takeshita et al., 2009 [26] | F/46 | ACTH Ca → NS | ~3 | <5 (−) | 150–200 × 5/28 (23) | CR tumor + METS | Required GC therapy |
|
Curtò et al., 2010 [27] | M/42 | ACTH Ca | 2–18 | <5 (−) | 150–200 × 5/28 (17) | Reduced (>90) | “Improved” |
|
Mohammed et al., 2009 [28] | F/43 | ACTH Ad | NA | (−) | 150–200 × 5/28 (12) | PR | “Improved” |
M/60 | ACTH Ca → NS | NA | (+) | 150–200 × 5/28 (12) | PR | “Improved” |
|
Bode et al., 2010 [29] | NA | ACTH Ca → NS | NA | NA | 150 × 5/28 | PR | NA |
|
Jouanneau et al., 2012 [30] | NA | SA → Ca | NA | NA | 200 × 5/28 | NR | NA |
|
Asimakopoulou et al., 2014 [31] | F/55 | ACTH Ad (Crooke cell) | 1 | NA | 150–200 × 5/28 | CR | CR |
|
Bengtsson et al., 2015 [32] | F/71 | ACTH Ad | 50 | 90 | 150–200 × 5/28 | SD | NA |
F/31 | GH Ad | 7 | 9–100 | 150–200 × 5/28 (6) | Reduced (50) | Regrowth after TMZ stop |
F/13 | GH Ad | 5 | 95 | 150–200 × 5/28 | NA | NA |
M/33 | PRL-GH Ad | 23 | 10 | 150–200 × 5/28 (3) | Reduced (35) | SD 25 months after TMZ |
M/22 | PRL Ad | 8 | 90 | 150–200 × 5/28 (15) | Reduced (25) | Death |
M/34 | PRL Ad | 6 | 9–100 | 150–200 × 5/28 (4) | Stable 40 m after TMZ | PR |
M/45 | PRL Ad | 2 | 100 | 150–200 × 5/28 (5) | Progression | PR |
M/55 | PRL Ad | 10 | 20 | 150–200 × 5/28 (11) | Reduced (66) | Death |
M/60 | PRL Ad | 2 | 9 | 150–200 + CAB (21) | Reduced (80) | Death |
M/68 | PRL Ad | NA | | 150–200 × 5/28 | Progression | Death |
M/23 | PRL Ad | 41 | 100 | 150–200 × 5/28 (4) | Progression | Death |
M/22 | NF Ad | 2 | 9 | 150–200 × 5/28 (12) | Reduced (55) | SD 69 m after TMZ |
M/45 | NF Ad | 2 | 100 | 150–200 × 5/28 (18) | Reduced (28) | NA |
F/52 | NF Ad | 10 | 90 | 150–200 × 5/28 (5) | Progression | Death |
M/59 | NF Ad | 10 | 90 | 150–200 × 5/28 (6) | Progression | Death |
M/57 | NF Ad | 3.3 | 95 | 150–200 × 5/28 | Progression | Death |
M/51 | ACTH Ca | 80 | 0–60 | 150–200 × 5/28 | NA | Death |
M/62 | ACTH Ca (NS) | 10 | 95 | 150–200 × 5/28 | NA | Lost to follow-up |
M/70 | ACTH Ca | 70 | 9 | 150–200 × 5/28 | NA | NA |
M/46 | GH Ca | 60 | 90 | 150–200 × 5/28 | NA | Death |
F/40 | GH Ca | 20 | 9 | 150–200 × 5/28 | CR | CR after 48 months |
F/49 | PRL-GH Ca | 5 | 9 | 150–200 × 5/28 | CR | CR after 91 months |
F/32 | PRL Ca | 20 | 50 | 150–200 × 5/28 | NA | Death |
F/59 | PRL Ca | 10 | NA | 150–200 × 5/28 | NA | PR |
|
Vieira Neto et al., 2013 [33] | F/54 | GH S Ca | 2.6 | 68 | 150–200 × 5/28 | SD | NA |
|
Morokuma et al., 2012 [34] | M/58 | NF Ca/NEM-1 | 7.6 | (−) | 75/d × 42 days; then 192 × 5/28 + RT (20) | “Visibly declined” | “Improved” |
|
Zhong et al., 2014 [35] | F/30 | NF Ad | 20 | NA | 200/d × 5/4 consecutive weeks/2 months + RT (4) | CR | NA |
|
Syro et al., 2009 [36] | M/70 | Gn Ad | 2–6 | 30–>50 | 200 × 5/28 (6) | “Minor reduction” and intratumoral necrosis | Death |
|
Hagen et al., 2009 [37] | F/48 | PRL Ad to mixed PRL-GH Ad to Ca | 5 | (−) | 150–200 + CAB/STT-A | Reduced (62) | “Improved” |
M/60 | PRL Ad | ~2 | (−) | 150–200 + CAB | Reduced (80) | “Improved” |
M/20 | NF Ad | ~2 | Few (+) | 150–200 | Reduced (55) | “Improved” |
|
Mendola et al., 2014 [38] | M/58 | NS Ca | 10 | NA | 160 × 5/28 (1) | No | No change |
|
Strowd et al., 2015 [39] | F/44 | PRL Ad | NA | NA | 150–200 × 5/28 (3 months) | “Reduction in tumor size” | PR |
|
Ceccato et al., 2015 [40] | F/67 | NF Ad | <3 | NA | 150–200 × 5/28 | Progression | No change |
F/39 | GH Ad | <3 | NA | 150–200 × 5/28 | Progression | No change |
M/40 | NF Ad | <3 | NA | 150–200 × 5/28 | Decreased (49) | NA |
M/32 | ACTH Ad | <3 | NA | 150–200 × 5/28 | Decreased (63) | No change |
M/47 | NF Ad → ACTH | <3 | NA | 150–200 × 5/28 + pasireotide | Decreased (21) | No change |
|
Philippon et al., 2012 [41] | M/41 | PRL Ca/MEN-1 | NA | NA | 200 × 5/28 (24) | Decreased (62) | “Improved” |
|
Fadul et al., 2006 [42] | M/38 | NF Ca | 1 | NA | 200 × 5/23 (12) | PR | PR |
M/26 | PRL Ca | 10 | | 200 × 5/23 (10) | PR | PR |
|
Kovacs et al., 2007 [43] | M/46 | PRL Ca | 40–60 | NA | 200 × 5/28 (7) | “Shrinkage” | “Improved” |
|
Cornell et al., 2013 [44] | M/40 | ACTH Ad | 5–7 | NA | 200 × 5/28 (3) | Progression | No change |
|
Phillips et al., 2012 [45] | M/25 | PRL Ad | 23 | NA | 350 × 5 (1) | No change | Death |
|
Rotondo et al., 2012 [46] | F/49 | Crooke cell Ad | 5–8 | (−) | 85 p.o daily + SRT | NA | NA |
|
Arnold et al., 2012 [47] | F/61 | ACTH Ca | NA | NA | NA (12) | “Resolved” | PR |
|
Morin et al., 2012 [48] | M/22 | GH Ad | 3-4 | NA | 200 × 5/28 (5) | No change | Increased signs |
|
Whitelaw et al., 2012 [49] | M/34 | PRL Ad | 15 | (−) | 200 × 5/28 (6) | “Dramatic reduction” | “Significant improvement” |
M/32 | PRL Ad | 8 | (−) | 200 × 5/28 (6) | “Substantial reduction” | “Significant improvement” |
M/13 | PRL Ad | 4 | (−) | 200 × 5/28 (12) | PR | PR |
|
Ersen et al., 2012 [50] | NA | Gn Ad | NA | Two zones: (−) and (+), 60% | 200 × 5/28 (14) | SD | “Clinical improvement” |
|
Scheithauer et al., 2012 [51] | F/13 months | Pituitary blastoma | NA | Varied from 40 to 60% | 100 × 5/28 (12 + 6) | Progression | NA |
|
Ortiz et al., 2012 [52] | M/38 | ACTH Ad → Ca | NA | High | 200 × 5/28 (8) | No change | Progression |
|
Batisse et al., 2013 [53] | M/47 | GH Ad | (−) | High | 200 × 5/28 (3) | Progression | No significant response |
|
Bruno et al., 2015 [4] | F/52 | ACTH Ad | 6 | (−) | 150–200 × 5/28 (29) | CR | CR |
F/42 | ACTH Ad | 4 | (−) | 150–200 × 5/28 (12) | CR | CR |
|